Navigation Links
ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:12/16/2009

lant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics

    Dr. Patrik De Haes, CEO                   Tel: +32-16-75-13-10
                                              patrik.dehaes@thrombogenics.com

    Dr. Steve Pakola, CMO                     Tel: +1-212-201-0920
                                              steve.pakola@thrombogenics.com

    Citigate Dewe Rogerson

    Amber Bielecka/David Dible/Nina Enegren   Tel: +44(0)207-638-95-71
                                              '/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , June 2 Today, the U.S. Food and Drug ... active ingredient known as a long-acting beta-agonist (LABA).  This follows the FDA ... medications to undertake class-labeling changes. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) , ...
... , June 2 GlaxoSmithKline (NYSE: ... a letter from the U.S. Food and Drug Administration ... Serevent® and Advair®.  The letter concludes discussions between GSK ... the safety profile of long-acting beta2-agonists in the treatment ...
Cached Medicine Technology:FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 2FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 3FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 4FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 5FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZeneca's SYMBICORT 6GSK Announces Revised Product Labels for Serevent® and Advair® 2
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
(Date:4/23/2014)... - Purdue University researchers have developed a way to ... by using tiny gold particles with tails of synthetic ... agricultural and biological engineering, used gold nanoparticles to target ... BRCA1 messenger RNA splice variants, which can indicate the ... these mRNA splice variants in a cell can be ...
(Date:4/23/2014)... targets an important brain receptor has a dramatic effect ... behavior, a University at Buffalo animal study has found. ... be a novel lead compound for treating cocaine addiction, ... was published as an online preview article in ... compound, RO5263397, severely blunted a broad range of cocaine ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... ... Flying Marijuana Bud Banner On Labor Day Weekend , ... Seattle, WA (PRWEB) September 4, 2009 -- When Labor Day crowds ... a flying marijuana bud on a massive banner along with the words "Want Big, Sugary ...
... ... Channel on the Fast Growth 100 list. The Fast Growth 100 recognizes the fastest growing ... , ... 4, 2009 -- Netelligent today announced that it has been recognized by Everything Channel on ...
... ... its short term medical insurance product to HCC Life Short Term Medical (STM). , ... Indianapolis, IN (PRWEB) September 3, 2009 ... term medical insurance product to HCC Life Short Term Medical (STM). Formerly known ...
... , , PALO ALTO, Calif., ... announced today that company management will present a corporate overview at ... Myers, President of Jazz Pharmaceuticals, will speak at the Rodman & ... 3:15 p.m. EDT at the Palace Hotel in New York City. ...
... say more research is needed , THURSDAY, Sept. 3 (HealthDay ... a new Danish study indicates they might also raise the ... and women. , That,s not to say fat thighs confer ... nearly 3,000 men and women who were followed for more ...
... , , , SAN FRANCISCO, ... will be ensuring expedited access to needed prescriptions and mental health ... California. , , "During this taxing and difficult ... people impacted by the wildfires to continue to have uninterrupted access ...
Cached Medicine News:Health News:Labor Day Beach Visitors Will See Giant Hydroponics Marijuana Bud Banner Flying Over Los Angeles & San Diego 2Health News:Labor Day Beach Visitors Will See Giant Hydroponics Marijuana Bud Banner Flying Over Los Angeles & San Diego 3Health News:Netelligent Recognized on the Everything Channel Fast Growth 100 List at #13 2Health News:Netelligent Recognized on the Everything Channel Fast Growth 100 List at #13 3Health News:HCC Life Insurance Company Renames Short Term Medical Insurance 2Health News:Thin Thighs Might Be Harbinger of Heart Disease 2Health News:Blue Shield of California Streamlines Access to Benefits and Prescriptions for Wildfire Victims 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Model C-18 is made of ... padding. Front and back sections ... larger openings to facilitate air ... is lightweight and washable. Model ...
Ezy Wrap® Economy Contour Cervical Collar Medium-density urethane foam. Synthetic white stockinette cover. Reverses for flexion or extension. (Contact closure. Hand wash. Air dry. 10/pack.)...
... improves patient compliance, prevent skin breakdown ... user's anatomy, wicks moisture, and evenly ... shoulders and upper throacic. Fits upright ... airflow openings. Adjustable Occipital Support Strap™ ...
Medicine Products: